SCHEMBL5043229

SCHEMBL5043229

O=C(O)c1ccc(CCCN(CCCc2cccc(Cl)c2)S(=O)(=O)Cc2ccccc2)s1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
PLAAT3 P53816 1/20 0.39
PLAAT5 Q96KN8 1/20 0.39
PLAAT2 Q9NWW9 1/20 0.39
PLAAT4 Q9UL19 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
AKR1C3 P42330 1/20 0.38
F2 P00734 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
RORC P51449 2/20 0.36
CSNK1D P48730 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5727230 0.91 TAS2R14 (0.39) TAS2R14SMN1; SMN2ALDH1A1HPGDPLAAT3
SCHEMBL5725567 0.88 TAS2R14 (0.37) TAS2R14SMN1; SMN2ALDH1A1HPGDPLAAT3
SCHEMBL5726690 0.88 MRGPRX4 (0.39) TAS2R14KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL5046905 0.88 TAS2R14 (0.50) TAS2R14KMT2AMEN1PLAAT3PLAAT5
SCHEMBL2769588 0.87 TAS2R14 (0.39) TAS2R14KMT2AMEN1PLAAT3PLAAT5
SCHEMBL5726508 0.87 ALDH1A1 (0.37) TAS2R14ALDH1A1HPGDPLAAT3PLAAT5
SCHEMBL5726407 0.86 TAS2R14 (0.39) TAS2R14KMT2AMEN1PLAAT3PLAAT5
SCHEMBL5726420 0.86 TAS2R14 (0.41) TAS2R14KMT2AMEN1PLAAT3PLAAT5
SCHEMBL5046539 0.85 HTT (0.45) TAS2R14KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL5046400 0.84 PTGER1 (0.37) TAS2R14PLAAT3PLAAT5PLAAT2PLAAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442702-B2 Treatment of bone disorders; carboxy derivatives PFIZER INC. (US) 2008-10-28 US disclosed
EP-1021410-B1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER (US) 2006-12-27 EP disclosed
EP-1601351-A1 USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT Pfizer Products Inc. (US) 2005-12-07 EP disclosed
US-20050203086-A1 Methods of treatment using an EP2 selective receptor agonist PFIZER INC. 2005-09-15 US disclosed
WO-2004078169-A1 USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT PFIZER PRODUCTS INC. (US) 2004-09-16 WO disclosed
US-20030078261-A1 Prostaglandin agonists CAMERON KIMBERLY O (US) 2003-04-24 US disclosed
US-6498172-B1 (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS PFIZER INC. 2002-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203086-A1 Methods of treatment using an EP2 selective receptor agonist PTGER2, PTGES2, PTGFR TAS2R14 518/4885KMT2A 2180/4885SMN1; SMN2 3228/4885
US-20030078261-A1 Prostaglandin agonists PTGER1, PTGER4, PTGIR TAS2R14 4081/4885KMT2A 3832/4885SMN1; SMN2 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.